Heterogeneity for integrin expression and cytokine‐mediated VLA modulation can influence the adhesion of human melanoma cells to extracellular matrix proteins

Expression of α and β subunits of VLA and VNR integrins was analyzed by cytofluorimetric analysis on 6 different human primary and metastatic melanoma cell cultures. Marked inter‐tumor heterogeneity was observed, and expression of VLA‐α, VLA‐α2 and VLA‐α6 was lower on primary melanomas than on metastatic lesions. The function of VLA products on melanoma cells was assessed by adhesion assays to extracellular matrix (ECM) proteins using a panel of melanoma clones previously characterized for the presence and heterogeneity of expression of the distinct VLA‐α subunits. These experiments indicated that intra‐tumor heterogeneity in the integrin profile can influence the interaction of neoplastic cells with ECM proteins. Inhibition of adhesion with antibodies to VLA‐α subunits revealed that the presence on melanoma cells of VLA‐α2, VLA‐α5 and VLA‐α6 is relevant for the adhesion to type‐IV collagen, fibronectin and laminin respectively. Culture of tumor cells in the presence of cytokines such as rIL‐1β, rTNF‐α, rIFN‐γ or TGF‐β could induce up‐ or down‐modulation in the level of expression of multiple VLA integrins. Cytokine‐mediated antigenic shifts in the VLA profile of melanoma cells were detected by cytofluorimetric analysis as early as 24 hr after cytokine exposure. The cytokine‐dependent change in the matrix receptor profile of melanoma cells also affected the adhesion to ECM proteins as revealed by the enhanced adhesion of rTNF‐α‐treated cells to fibronectin. These data indicate that constitutive heterogeneity in the integrin profile or cytokine‐mediated shifts in VLA expression can affect the ability of human melanoma cells to interact with different ECM components.

[1]  R. Supino,et al.  Human melanoma cells with high susceptibility to cell‐mediated lysis can be identified on the basis of icam‐1 phenotype, vla profile and invasive ability , 1990, International journal of cancer.

[2]  R. Kramer,et al.  Human microvascular endothelial cells use beta 1 and beta 3 integrin receptor complexes to attach to laminin , 1990, The Journal of cell biology.

[3]  A. Sonnenberg,et al.  The alpha 1/beta 1 and alpha 6/beta 1 integrin heterodimers mediate cell attachment to distinct sites on laminin , 1990, The Journal of cell biology.

[4]  E. Ruoslahti,et al.  A novel fibronectin receptor with an unexpected subunit composition (alpha v beta 1). , 1990, The Journal of biological chemistry.

[5]  W. Carter,et al.  The role of integrins alpha 2 beta 1 and alpha 3 beta 1 in cell-cell and cell-substrate adhesion of human epidermal cells , 1990, Journal of Cell Biology.

[6]  H. Larjava,et al.  Differences in the biosynthesis and localization of the fibronectin receptor in normal and transformed cultured human cells. , 1990, Cancer research.

[7]  M. Elices,et al.  VCAM-1 on activated endothelium interacts with the leukocyte integrin VLA-4 at a site distinct from the VLA-4/Fibronectin binding site , 1990, Cell.

[8]  A. Anichini,et al.  Cytokine‐mediated modulation of HLA‐class II, ICAM‐1, LFA‐3 and tumor‐associated antigen profile of melanoma cells. comparison with anti‐proliferative activity by RIL1‐β, RTNF‐α, RIFN‐γ, RIl4 and their combinations , 1990 .

[9]  S. Ferrone,et al.  Differential expression of intercellular adhesion molecule 1 in primary and metastatic melanoma lesions. , 1990, Cancer research.

[10]  J. Massagué,et al.  Transforming growth factor-beta switches the pattern of integrins expressed in MG-63 human osteosarcoma cells and causes a selective loss of cell adhesion to laminin. , 1989, The Journal of biological chemistry.

[11]  E. Ruoslahti,et al.  Integrins and tumor cell dissemination. , 1989, Cancer cells.

[12]  M. Elices,et al.  The human integrin VLA-2 is a collagen receptor on some cells and a collagen/laminin receptor on others. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[13]  W. Clark,et al.  Antigenic profile of tumor progression stages in human melanocytic nevi and melanomas. , 1989, Cancer research.

[14]  C. Mueller-Eckhardt,et al.  The Bra/Brb alloantigen system on human platelets. , 1989, Blood.

[15]  A. Anichini,et al.  Cytotoxic T lymphocyte clones from peripheral blood and from tumor site detect intratumor heterogeneity of melanoma cells. Analysis of specificity and mechanisms of interaction. , 1989, Journal of immunology.

[16]  M. Mareel,et al.  Acquisition of tumorigenic potential in the human myoepithelial HBL100 cell line is associated with decreased expression of HLA class I, class II and integrin β3 and increased expression of c‐myc , 1989, International journal of cancer.

[17]  Jeffrey W. Smith,et al.  A novel vitronectin receptor integrin (α v β x ) is responsible for distinct adhesive properties of carcinoma cells , 1989, Cell.

[18]  J. A. Mourik,et al.  Human vascular endothelial cells express a membrane protein complex immunochemically indistinguishable from the platelet VLA-2 (glycoprotein Ia-IIa) complex , 1989 .

[19]  V. Quaranta,et al.  A novel integrin (alpha E beta 4) from human epithelial cells suggests a fourth family of integrin adhesion receptors. , 1989, The EMBO journal.

[20]  S. Dedhar Regulation of expression of the cell adhesion receptors, integrins, by recombinant human interleukin‐1β in human osteosarcoma cells: Inhibition of cell proliferation and stimulation of alkaline phosphatase activity , 1989, Journal of cellular physiology.

[21]  R. Hynes,et al.  Changes in integrin receptors on oncogenically transformed cells , 1989, Cell.

[22]  L. Liotta,et al.  Modulation of laminin receptor expression by estrogen and progestins in human breast cancer cell lines. , 1988, Journal of the National Cancer Institute.

[23]  T. Springer,et al.  ICAM-1 a ligand for LFA-1-dependent adhesion of B, T and myeloid cells , 1988, Nature.

[24]  W. Carter,et al.  Identification of multiple cell adhesion receptors for collagen and fibronectin in human fibrosarcoma cells possessing unique alpha and common beta subunits , 1987, The Journal of cell biology.

[25]  A. Anichini,et al.  Phenotypic profile of clones from early cultures of human metastatic melanomas and its modulation by recombinant interferon γ , 1986, International journal of cancer.

[26]  M. Horton,et al.  Monoclonal antibodies to osteoclastomas (giant cell bone tumors): definition of osteoclast-specific cellular antigens. , 1985, Cancer research.

[27]  N. Hogg,et al.  Monoclonal antibodies specific for platelet glycoproteins react with human monocytes. , 1984, Blood.

[28]  P. Lansdorp,et al.  Monoclonal antibodies against human platelet glycoprotein IIIa , 1983, British journal of haematology.

[29]  S. Ferrone,et al.  Molecular heterogeneity and shedding of a high-molecular-mass melanoma-associated antigen identified with monoclonal antibodies. , 1982, Clinical chemistry.

[30]  R. Accolla,et al.  Distinct forms of both alpha and beta subunits are present in the human Ia molecular pool. , 1981, Proceedings of the National Academy of Sciences of the United States of America.

[31]  M. Hemler VLA proteins in the integrin family: structures, functions, and their role on leukocytes. , 1990, Annual review of immunology.

[32]  J. V. van Mourik,et al.  Human vascular endothelial cells express a membrane protein complex immunochemically indistinguishable from the platelet VLA-2 (glycoprotein Ia-IIa) complex. , 1989, Blood.

[33]  M. Herlyn,et al.  Melanoma antigens: immunological and biological characterization and clinical significance. , 1988, Annual review of immunology.

[34]  H. Strander Interferon treatment of human neoplasia. , 1986, Advances in cancer research.

[35]  L. Liotta Tumor invasion and metastases--role of the extracellular matrix: Rhoads Memorial Award lecture. , 1986, Cancer research.

[36]  L. Liotta,et al.  Laminin receptor on human breast carcinoma cells. , 1983, Proceedings of the National Academy of Sciences of the United States of America.